A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.
Also called NCT03736785
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 399 participants
- Sponsor
- Registry
-
NCT03736785
-
- Other papers using this trial's data
- Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT03736785. Randomized; no masking; primary purpose treatment. Start 2018-11-15 (actual); primary completion 2020-02-18 (actual). Results posted on 2021-03-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LY3209590
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03736785- Content hash
7f5170bed23de87e52a2e0ade206bbd8de4ae3a8de887479a0058a5f22d4a80a